M-Segment DNA Vaccine for Cross-Strain CCHFV Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CCHF vaccines face challenges in providing cross-protection against divergent strains due to high genetic diversity and lack of understanding of the necessary immune responses for effective protection, with existing vaccines often focusing on homologous challenges and not adequately addressing heterologous protection.
Innovation Solution
Development of a simplified DNA vaccine expressing the M-segment of clinically relevant CCHFV strains, specifically CCHFV-Afg09-2990, and investigating the role of non-structural protein GP38 in immune response, using a single plasmid formulation to elicit both humoral and cellular immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines focus on homologous challenges with specific strains, then protection against that specific strain is improved, but cross-protection against divergent strains deteriorates
Solution Approach 1:
The vaccine composition is designed to provide universal protection against multiple CCHFV strains by incorporating antigens from diverse viral strains, enabling a single vaccine to elicit immune responses that recognize both homologous and heterologous viruses
Solution Approach 2:
The vaccine uses composite antigen formulations combining multiple CCHFV strain components (such as Gn, Gc, and N proteins from different strains) to create a multi-component immunogen that triggers broad-spectrum immunity against genetically diverse viruses
2Adaptability or versatility
If vaccine formulations include multiple components to address genetic diversity, then cross-protection is improved, but device complexity deteriorates
Solution Approach 1:
Multiple CCHFV antigen components from different strains are merged into a single vaccine formulation, combining Gn, Gc, and N proteins in one composition that can be administered as a unified vaccine product rather than multiple separate injections
Solution Approach 2:
The complex antigen composition is segmented into distinct functional components (Gn, Gc, N proteins) that can be independently characterized and optimized, allowing systematic development of multi-component vaccines with defined roles for each antigen
3Ease of manufacture
If vaccines target only structural glycoproteins, then manufacturing is simplified, but immune response completeness deteriorates
Solution Approach 1:
The vaccine targets are segmented into multiple functional protein categories (Gn, Gc structural glycoproteins and N nucleocapsid protein), allowing separate expression and purification of each component while maintaining manufacturing feasibility through modular production approaches
Data Source
AI summary
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Here, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene (GPC) of the laboratory CCHFV strain CCHFV-IbAr 10200 (CCHFV-M10200). Increasing the dose of CCHFV-M 10200 provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant, heterologous CCHFV-Afg09-2990 strain. We also report complete protection from CCHFV-Afg09-2990 challenge following vaccination with a CCHFV-Afg09-2990 GPC expressing DNA vaccine (CCHFV-M Afgog). Finally, we show that the non-structural M-segment protein, GP38, influences CCHF vaccine immunogenicity and provides significant protection from homologous CCHFV challenge. Our results demonstrate that M-segment DNA vaccines elicit protective CCHF immunity and further illustrate the immunorelevance of GP38.